ArticleCancer cell international2026
Exosomal lncRNA NORAD drives oxaliplatin resistance in AEG via the miR-433-3p/autophagy axis: a novel mechanism and potential biomarker.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOxaliplatin resistance poses a substantial therapeutic challenge in adenocarcinoma of the esophagogastric junction (AEG). Although the lncRNA NORAD has been implicated in chemoresistance, its specific role, underlying mechanism, and clinical significance in AEG remain unclear. We hypothesize that exosome-derived NORAD promotes oxaliplatin resistance via a competing endogenous RNA network that modulates autophagy and may serve as a potential circulating biomarker.
methodsThe expression levels of NORAD and miR-433-3p were analyzed in 56 paired AEG tumor and adjacent normal tissues, as well as in AEG cell lines (OE19, PDC) and their corresponding oxaliplatin-resistant derivatives (OE19-R, PDC-R), using quantitative real-time polymerase chain reaction. The direct interaction between NORAD and miR-433-3p was validated by dual-luciferase reporter assay. Functional consequences of NORAD knockdown were assessed: cell viability was determined by CCK-8 assay to calculate the half-maximal inhibitory concentration (IC₅₀); autophagic flux was evaluated by western blotting for the LC3B-Ⅱ/LC3B-I ratio and p62 degradation; and apoptosis was quantified by flow cytometry. Serum exosomal NORAD levels were measured in AEG patients and healthy controls.
resultsIn AEG tissues, NORAD was significantly upregulated, whereas miR-433-3p was downregulated, and a strong inverse correlation was observed between them (r = -0.864, p < 0.001). NORAD directly bound to miR-433-3p, acting as a molecular sponge. Oxaliplatin-resistant cells exhibited elevated NORAD levels, enhanced autophagic flux-characterized by an increased LC3B-Ⅱ/I ratio and decreased p62 levels-and a higher IC₅₀ value. Silencing NORAD resensitized the resistant cells to oxaliplatin (e.g., IC₅₀ in PDC-R decreased from 22.27 to 2.51 µg/mL), inhibited autophagy, and promoted apoptosis. Clinically, serum exosomal NORAD levels were significantly elevated in AEG patients, and a strong positive correlation was observed between serum exosomal NORAD levels and tumor NORAD expression (r = 0.886, p < 0.001).
conclusionOur study identifies a novel NORAD/miR-433-3p/autophagy axis driving oxaliplatin resistance in AEG. Targeting NORAD restores chemosensitivity, highlighting its therapeutic potential. Moreover, circulating exosomal NORAD serves as a promising non-invasive biomarker, supporting its application in liquid biopsy for AEG management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.